Cardiovascular Drugs and Therapy最新文献

{"title":"Local Pericardial Delivery of Bone Marrow-Derived Extracellular Vesicles: A Novel Therapeutic Approach for HfmrEF.","authors":"Xingyue Feng, Xinyu Nie, Can Xu","doi":"10.1007/s10557-025-07776-0","DOIUrl":"https://doi.org/10.1007/s10557-025-07776-0","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the Correspondence Regarding: \"Short-Course Potent P2Y12 Inhibitor-Based DAPT Versus Clopidogrel-Based DAPT After PCI: A Propensity-Matched Real-World Study\".","authors":"Natchanon Kulsumritpon","doi":"10.1007/s10557-025-07779-x","DOIUrl":"https://doi.org/10.1007/s10557-025-07779-x","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of TriClip Procedure in Patients with Severe Tricuspid Regurgitation and Large Coaptation Gap.","authors":"Zeynettin Kaya, Fuat Polat, Ufuk İyigün, Cuma Süleymanoğlu, Gamze Yeter Arslan, İsmail Ateş","doi":"10.1007/s10557-025-07775-1","DOIUrl":"https://doi.org/10.1007/s10557-025-07775-1","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate the safety and efficacy of transcatheter tricuspid valve repair using the TriClip system in patients with severe tricuspid regurgitation (TR) and large coaptation gaps (> 10 mm), a subgroup traditionally considered anatomically challenging for edge-to-edge repair.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 9 symptomatic patients who underwent TriClip implantation at multiple centers in Turkey between March 2024 and May 2025. All patients had severe or greater TR with coaptation gaps exceeding 10 mm and were deemed high-risk for surgical intervention. Clinical and echocardiographic parameters were collected before and after the procedure.</p><p><strong>Results: </strong>The mean age of patients was 68.4 ± 8.6 years. The average coaptation gap was 17.56 ± 3.43 mm. The procedure achieved 100% technical success, defined as at least a one-grade reduction in TR severity. The mean number of clips implanted was 3.22 ± 0.83, with the XTW clip used in 86.3% of cases. No major complications or in-hospital mortality occurred. Symptomatic improvement was observed in all patients, with most experiencing at least one New York Heart Association (NYHA) class reduction. Mean follow-up duration was 6.7 ± 2.4 months.</p><p><strong>Conclusion: </strong>TriClip repair appears to be a safe and effective therapeutic option in high-risk patients with severe TR and large coaptation gaps. Despite anatomical complexity, significant reductions in TR severity and clinical symptoms were achieved, with low complication rates. These findings support the feasibility of TriClip therapy in this challenging patient population.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Crocetin in Post-Myocardial Infarction Fibrosis: Translational Barriers and the Need for Pharmacokinetic and Pharmacodynamic Evidence.","authors":"Noor-Ul-Eman Haider, Mehwish Amjad","doi":"10.1007/s10557-025-07774-2","DOIUrl":"https://doi.org/10.1007/s10557-025-07774-2","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients.","authors":"Shriya Chunduri, Ghassan Bidaoui, Mohammad H Hussein, Milee Patel, Ahmed Abdelmaksoud, Mohamed Mohamed, Abdallah Attia, Danielle Tatum, Jamil Borgi, Eman A Toraih","doi":"10.1007/s10557-025-07757-3","DOIUrl":"https://doi.org/10.1007/s10557-025-07757-3","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the effectiveness of tirzepatide (a dual GLP-1/GIP receptor agonist) versus semaglutide (a GLP-1 receptor agonist) in improving postoperative outcomes among patients with type 2 diabetes mellitus (T2DM) undergoing coronary artery bypass grafting (CABG).</p><p><strong>Methods: </strong>We conducted a retrospective analysis using the TriNetX global research network, identifying 226,742 adults with T2DM who underwent isolated CABG between 2022 and 2024. Among these, 3,669 received tirzepatide and 19,521 received semaglutide. After 1:1 propensity score matching, 3,667 matched pairs were analyzed. Primary outcomes included cerebrovascular and cardiovascular events, postoperative complications, healthcare utilization, and all-cause mortality, assessed at 6-month and 3-year intervals. P-values were adjusted for multiple testing using the Benjamini-Hochberg procedure.</p><p><strong>Results: </strong>Tirzepatide was associated with significantly lower risks of cerebrovascular events at both follow-up points, including reduced incidence of cerebrovascular disease (11.8% vs. 17.5%; HR = 0.831), cerebral infarction (4.6% vs. 7.3%; HR = 0.788), and cerebral occlusion without infarction (6.8% vs. 10.4%; HR = 0.838)-all of which remained statistically significant after multiple comparison correction (adjusted p = 0.0024). Cardiovascular outcomes also favored tirzepatide, with significant reductions in major adverse cardiovascular events (MACE) (39.7% vs. 49.5%; HR = 0.911), myocardial infarction (7.0% vs. 10.8%; HR = 0.838), and acute coronary disease (1.1% vs 2.3%; HR = 0.691); several of these remained significant after correction at both timepoints. While tirzepatide was associated with lower rates of surgical site infection, venous thrombosis, and CABG-specific complications, only venous thrombosis remained statistically significant after adjustment (adjusted p = 0.021). Additionally, tirzepatide users had reduced healthcare utilization and lower all-cause mortality, with 3-year readmission (16.4% vs. 23.4%; HR = 0.871) and mortality (1.9% vs. 4.7%; HR = 0.595) both remaining significant after adjustment (adjusted p = 0.002). Kaplan-Meier analysis confirmed sustained survival benefit.</p><p><strong>Conclusion: </strong>In patients with T2DM undergoing CABG, tirzepatide was associated with improved cerebrovascular and cardiovascular outcomes, reduced venous thrombotic complications, and lower long-term mortality and healthcare utilization compared to semaglutide. These findings support the therapeutic potential of dual GLP-1/GIP receptor agonism in high-risk post-CABG populations.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exosomes from Stem Cells: A Future Alternative to Whole-Cell Therapy in Heart Failure.","authors":"Ahmed Bashir, Muhammad Bashir, Muhammad Aman Rizwan","doi":"10.1007/s10557-025-07777-z","DOIUrl":"https://doi.org/10.1007/s10557-025-07777-z","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Lipid-Lowering Strategies Beyond Current Evidence.","authors":"Mucahit Yetim, Abdülmelik Birgün, Macit Kalçık","doi":"10.1007/s10557-025-07778-y","DOIUrl":"https://doi.org/10.1007/s10557-025-07778-y","url":null,"abstract":"<p><p>This letter addresses the recent study by Sohn et al., which compared moderate-intensity atorvastatin plus ezetimibe with high-intensity atorvastatin in patients with angina undergoing PCI. We emphasize key limitations, including the absence of LDL-C values, potential residual confounding, and the small CKD subgroup sample size. Furthermore, adherence and safety outcomes were not adequately assessed. While the study supports non-inferiority of combination therapy, further prospective research is needed to clarify optimal lipid-lowering strategies in this high-risk population.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thorough Physiological Assessment in Non-Culprit Vessels of Patients with Acute Myocardial Infarction: Is It a Required Action?","authors":"Zining Chen, Yuxuan Zhang, Jiacheng Fang, Yiyue Zheng, Delong Chen, Abuduwufuer Yidilisi, Xinyi Zhang, Chi Liu, Jiniu Huang, Rui Ji, Jiamu Chen, Guohui Chen, Ping Lin, Yumeng Hu, Jianping Xiang, Jian'an Wang, Jun Jiang","doi":"10.1007/s10557-025-07768-0","DOIUrl":"https://doi.org/10.1007/s10557-025-07768-0","url":null,"abstract":"<p><strong>Backgrounds: </strong>The management of non-culprit vessels (NCV) among individuals with acute myocardial infarction (AMI) remains an unsolved problem. Angiography-derived physiological assessments developed recently may help address this issue. Our study aims to measure angiography-derived fractional flow reserve (Angio-FFR) and angiography-derived index of microcirculatory resistance (Angio-IMR) in NCVs of AMI patients and explore their prognostic values and necessity.</p><p><strong>Methods: </strong>This retrospective cohort study enrolled AMI patients with multivessel disease (MVD) who were routinely followed up for 2 years. Angio-FFR and Angio-IMR were measured in NCVs with 40%-80% visual stenosis. The primary endpoint was defined as the vessel-oriented composite endpoint (VOCE), comprising cardiac death, target vessel myocardial infarction, and ischemia-driven target vessel revascularization.</p><p><strong>Results: </strong>A total of 503 patients and 712 NCVs were retrospectively included. NCVs with Angio-FFR ≤ 0.8 had significantly higher hazards of VOCE (27% vs. 12.6%, P < 0.001), contrarily, Angio-IMR groups divided by 25 exhibited no significant discrepancy (15.15% vs. 11.04%, P = 0.383). Multivariate Cox regression identified Angio-FFR as an independent predictor of VOCE (HR: 1.70, 95% CI: 1.01-2.84, P < 0.05), whereas Angio-IMR did not (HR: 0.88, 95% CI: 0.43-1.79, P > 0.05). Such correlation was consistent in subgroup analysis and propensity score matching.</p><p><strong>Conclusions: </strong>The prognosis of NCVs in AMI patients correlated with Angio-FFR but not with Angio-IMR, indicating it is epicardial vessel occlusion rather than microcirculatory dysfunction, predominantly leading to additional adverse prognosis. Compared to Angio-FFR, measuring Angio-IMR could be of limited necessity and clinical value in the management of NCVs among AMI patients.</p><p><strong>Trial registration: </strong>URL: https://www.</p><p><strong>Clinicaltrials: </strong>gov .  Unique identifier: NCT05696379.  Study Registration Dates: 2022-12-13.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145005954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: Real-World Efficacy of Inclisiran in Veneto Region (Italy)-Two-thirds at Target, What About the Others?","authors":"Luca Bonanni","doi":"10.1007/s10557-025-07773-3","DOIUrl":"https://doi.org/10.1007/s10557-025-07773-3","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Role of Andexanet Alfa in Managing Intracranial Hemorrhage in Patients on Vascular-Dose Rivaroxaban: A Clinical Dilemma.","authors":"Matija Zupan, Pawel Kermer, Senta Frol","doi":"10.1007/s10557-025-07772-4","DOIUrl":"https://doi.org/10.1007/s10557-025-07772-4","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144944081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}